Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Surufatinib · HMPL-012

Small molecule · Inhibitor of vascular endothelial growth factor receptor 1 (FLT1), vascular endothelial growth factor receptor 2 (KDR) and vascular endothelial growth factor receptor 3 (FLT4) · developed by Hutchmed

Phase 2/3 Most advanced trial
HCM Developer
3 Registered trials

What is Surufatinib?

Surufatinib is an orally bioavailable small molecule that inhibits vascular endothelial growth factor receptors 1, 2 and 3 and fibroblast growth factor receptor 1, reducing angiogenesis and tumor cell proliferation. It is being studied in solid tumors including pancreatic, colorectal, neuroendocrine, small cell lung, gastric, and ovarian cancers, soft tissue sarcoma, and anaplastic thyroid cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
HMPL-012
Drug type
Small molecule
Targets
vascular endothelial growth factor receptor 1 (FLT1), vascular endothelial growth factor receptor 2 (KDR), vascular endothelial growth factor receptor 3 (FLT4), fibroblast growth factor receptor 1 (FGFR1)
Mechanism
Inhibitor of vascular endothelial growth factor receptor 1 (FLT1), vascular endothelial growth factor receptor 2 (KDR) and vascular endothelial growth factor receptor 3 (FLT4)
Pathways
angiogenesis, VEGFR signal transduction, FGFR1 signal transduction, tumor cell proliferation
Therapy area
Oncology
Developer
Hutchmed (HCM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
B2K5L1L8S9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06361888 Phase 2/3 Metastatic Pancreatic Cancer Recruiting HCM
NCT05494580 Phase 1/2 Ovarian Cancer Completed HCM
NCT04579757 Phase 1/2 Metastatic Solid Tumor Terminated HCM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Pancreatic CancerAnaplastic Thyroid CancerColorectal CancerFallopian Tube CarcinosarcomaGastric CancerMetastatic Solid TumorNeuroendocrine TumorsOvarian CancerOvarian CarcinomaPlatinum-resistant Ovarian CancerPrimary Peritoneal CancerSmall Cell Lung CancerSoft Tissue Sarcoma

Other drugs acting on FLT1 / KDR / FLT4 / FGFR1

More from Hutchmed

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.

Follow HCM, the company behind Surufatinib

See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HCM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.